An International, Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk Of Major Thrombotic Vascular Events in Patients with Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures
Principal Investigator (?)
The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
Bayer HealthCare Pharmaceuticals, Inc
Available at the following location(s)